VYNE Therapeutics Inc. VYNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-70.34
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $570,000 | -$26.5M | — | — | $27.8M |
| 2024 | $501,000 | -$39.8M | — | — | $52.1M |
| 2023 | $424,000 | -$28.5M | — | — | $88.7M |
| 2022 | $477,000 | -$23.2M | — | — | $31.2M |
| 2021 | $931,000 | -$73.3M | — | -$56.4M | $48.6M |
| 2020 | $21.0M | -$255.6M | — | -$137.2M | $37.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Domzalski David | PRESIDENT AND CEO | 2026-05-29 | Grant | 30,791 | $0.31 |
| Zeronda Tyler | CHIEF FINANCIAL OFFICER | 2026-03-31 | Tax withheld | 4,007 | $0.60 |
| Stuart Iain | CHIEF SCIENTIFIC OFFICER | 2026-03-31 | Tax withheld | 2,876 | $0.60 |
| Harsch Mutya | CHIEF LEGAL OFFICER AND GC | 2026-03-31 | Tax withheld | 4,007 | $0.60 |
| Domzalski David | PRESIDENT AND CEO | 2026-03-31 | Tax withheld | 14,232 | $0.60 |
| Domzalski David | PRESIDENT AND CEO | 2025-12-31 | Tax withheld | 12,684 | $0.58 |
| Zeronda Tyler | CHIEF FINANCIAL OFFICER | 2025-12-31 | Tax withheld | 7,858 | $0.58 |
| Stuart Iain | CHIEF SCIENTIFIC OFFICER | 2025-12-31 | Tax withheld | 2,448 | $0.58 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -70.34 (distress)
- Working capital / assets 0.916
- Retained earnings / assets -25.121
- EBIT / assets -0.986
- Equity / liabilities 11.593
Source: SEC EDGAR filings · CIK 0001566044 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.